Aktis Oncology Inc (AKTS)

Mar 04, 2026

Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks

Mar 04, 2026

Mar 03, 2026

AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView

Mar 03, 2026

Mar 03, 2026

AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView

Mar 03, 2026

Feb 28, 2026

BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 28, 2026

AKTS Technical Analysis & Stock Price Forecast - Intellectia AI

Feb 28, 2026

Feb 27, 2026

IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace

Feb 27, 2026

Feb 25, 2026

Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance

Feb 25, 2026

Feb 25, 2026

Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks

Feb 25, 2026

Feb 24, 2026

Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times

Feb 24, 2026

Feb 24, 2026

Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat

Feb 24, 2026

Feb 24, 2026

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget

Feb 24, 2026

Feb 24, 2026

Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Aktis Oncology's AKY-1189 Wins FDA Fast Track Designation - Nasdaq

Feb 24, 2026

Feb 23, 2026

Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com

Feb 23, 2026

Feb 23, 2026

Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com

Feb 23, 2026

Feb 23, 2026

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters

Feb 23, 2026

Feb 18, 2026

Ken Herrmann Net Worth (2026) - GuruFocus

Feb 18, 2026

Feb 17, 2026

US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma

Feb 17, 2026

Feb 17, 2026

Huge insider buying now at this insurance giant and 2 biotechs - MSN

Feb 17, 2026

Feb 10, 2026

2026 kicks off with $10.8B January financing haul - BioWorld MedTech

Feb 10, 2026

Feb 05, 2026

Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut - WTVB

Feb 05, 2026

Feb 05, 2026

Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech

Feb 05, 2026

Feb 04, 2026

Eikon Therapeutics raises $381M in IPO - Axios

Feb 04, 2026

Feb 04, 2026

Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com

Feb 04, 2026

Feb 03, 2026

Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360

Feb 03, 2026

Feb 03, 2026

This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga

Feb 03, 2026

Feb 03, 2026

Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks

Feb 03, 2026

Jan 28, 2026

Merck veteran Perlmutter-led Eikon ‍Therapeutics eyes $908 million valuation in IPO - Reuters

Jan 28, 2026

Jan 28, 2026

Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com

Jan 28, 2026

Jan 28, 2026

Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech

Jan 28, 2026

Jan 27, 2026

Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com

Jan 27, 2026

Jan 27, 2026

Aktis Oncology prices IPO at $18 per share - MSN

Jan 27, 2026

Jan 20, 2026

Why Revolution Medicines Stock Surged by 11% Today - AOL.com

Jan 20, 2026

Jan 19, 2026

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com

Jan 19, 2026

Jan 19, 2026

Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com

Jan 19, 2026

Jan 19, 2026

‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times

Jan 19, 2026

Jan 18, 2026

Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance

Jan 18, 2026

Jan 16, 2026

AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan

Jan 16, 2026

Jan 16, 2026

United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq

Jan 16, 2026

Jan 15, 2026

Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria

Jan 15, 2026

Jan 15, 2026

Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack By Investing.com - Investing.com South Africa

Jan 15, 2026

Jan 15, 2026

Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal

Jan 15, 2026

Jan 14, 2026

Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks

Jan 14, 2026

Jan 14, 2026

Aktis Oncology director Foley buys $4.19 million in shares By Investing.com - Investing.com India

Jan 14, 2026

Jan 14, 2026

Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria

Jan 14, 2026

Jan 14, 2026

Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com

Jan 14, 2026

Jan 14, 2026

Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com South Africa

Jan 14, 2026